Recipharm’s full range Oral Solid Dosage (OSD) capabilities meet growing industry demands

• Full range OSD development and manufacturing capabilities from orphan drugs to blockbusters
• High potency manufacturing capabilities expansion
• Introduction of ReciPredict platform to accelerate product development and de-risk tech transfer
• API capabilities from route scouting to large scale synthesis

Recipharm, a leading global contract development and manufacturing organisation (CDMO), has significantly enhanced its capabilities in the development and production of orally delivered drug products. With a strong legacy in API development, product development and manufacturing expertise, Recipharm continues to offer cutting-edge, innovative solutions.

“We are dedicated to delivering innovative, end-to-end solutions that help our customers bring high-quality drug products to market efficiently” said Greg Behar, CEO at Recipharm. “Our advanced capabilities in oral dose formulations, coupled with our state-of-the-art API development services, allow us to support every stage of the product lifecycle. With the current investments in our oral product development capabilities in Germany and India and the addition of our ReciPredict platform, we are able to accelerate timelines, improve cost efficiency and enhance process reliability during product development, Tech Transfers and life cycle management. This comprehensive approach ensures that we can manage even the most complex projects, helping our customers achieve the best outcomes for their patients.”

High potency manufacturing capabilities

Responding to increasing market demand, Recipharm has expanded its high-potency manufacturing capabilities.

Greg Behar, CEO, continues: “Our existing high potency manufacturing suite enables Recipharm to collaborate with pharmaceutical companies on manufacturing advanced treatments, including oncology drugs and other highly potent medicines, while adhering to the highest safety and compliance standards.”

Flexible, adaptable and comprehensive solutions

Recipharm’s capabilities in oral solid dosage forms span the full product lifecycle, from pre-formulation and formulation development to clinical supply and large scale commercial manufacturing and packaging. Its state-of-the-art facilities are equipped to manage the full range of technologies for oral products, covering solids, semi-solids and liquids. Recipharm will continue to invest and to collaborate with strategic partners to further enhance our offerings and support launches of innovative medicines.

Recipharm provides end-to-end API development services, from pre-clinical stages through to commercial supply. This includes advanced flow chemistry capabilities for high purity API production and GMP small batch quantities for specialised APIs as well as full scale API synthesis.

In addition, the group has made strategic investments to support blockbuster drug production, ensuring it can meet the demands of the rapidly evolving pharmaceutical market. By utilising cutting-edge technologies, Recipharm helps bring life-saving treatments to market faster.

Efficiency and reliability in accelerated product development using ReciPredict

Recipharm’s ReciPredict is a cutting-edge platform for Quality by Design (QbD), designed to further improve the landscape of drug product development, tech transfers and manufacturing. It accelerates new drugs’ journey to the clinical stage by 3-6 months, offers significant cost savings by reducing API and material consumption by 30% to 70% and de-risks tech transfers by identifying the right parameters for best process robustness, consequently achieving consistent and high-quality results from proof of concept to clinic and subsequent commercial supply.

Advanced manufacturing and packaging technologies

Recipharm’s OSD manufacturing capabilities are further supported by advanced technologies, including:

• Wet, dry and spray granulation
• Direct compression
• Fluid bed granulation
• High shear granulation
• Tablet imprinting and coating
• Semi-Solid and liquid oral technologies
• Integrated primary and secondary packaging solutions

These technologies, along with analytical services, stability testing and regulatory support, enable Recipharm to deliver high-quality products efficiently and cost-effectively.

Regulatory approvals

With regulatory approvals from major authorities such as the US FDA, EMA, ANVISA and others, Recipharm offers a truly global solution for the pharmaceutical industry. Its network of facilities across Europe and India ensures that client have access to a wide range of regulatory expertise, helping to navigate the complexities of global drug development and manufacturing. 

Recipharm’s continued investment in cutting-edge technologies and its deep pharmaceutical expertise solidify its position as a leading, trusted partner for pharmaceutical companies worldwide, from small-scale clinical trial production to blockbuster commercial manufacturing.

A network of strategically-positioned sites

Recipharm’s nine OSD sites located in Germany, India, Israel, Italy, Portugal, Spain and Sweden provide the agility and sharp focus required to respond to customers’ needs and offer capabilities in either New Chemical Entities (NCEs), medium to high potency and on-patent drugs.

Those sites operate in close coordination with other Recipharm sites within the SFF and the ATMP segments.

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,200 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its ReciBioPharm division works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US and is headquartered in Stockholm, Sweden.

For more information on Recipharm, please visit www.recipharm.com and www.recibiopharm.com

Media contact:
Guenaelle Holloway, Head of communications
Guenaelle.Holloway@recipharm.com
+44 7730 303 708

Recipharm AB 
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com

Tags: